Carmen Lacambra

Learn More
Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by germline mutations in the VHL gene. This gene, located in the 3p25-26 chromosome, is a tumor suppressor gene associated with the inhibition of angiogenesis and apoptosis, cell cycle exit, fibronectin matrix assembly, and proteolysis. To define the molecular basis of VHL in a Spanish(More)
The pathologic and immunohistochemical features of familial epithelial ovarian cancers are not well understood. We have carried out a comprehensive immunohistochemical study of familial ovarian carcinomas from women with and without BRCA1 or BRCA2 mutations, in order to identify specific and/or common features among these different familial case groups(More)
The clinical case of a patient suffering AIDS who presented a progressive multifocal leukoencephalopathy (PML), diagnosed by CT scan, magnetic resonance imaging (MRI) and cerebral biopsy, is here described. A therapeutic trial was carried out with zidovudine (200 mg/4 hours p.o.) during 75 days. Although this treatment diminished the number of infections, a(More)
In the front line Shoreline protection and other ecosystem services from mangroves and coral reefs In the front line THE UNITED NATIONS ENVIRONMENT PROGRAMME WORLD CONSERVATION MONITORING CENTRE (UNEP-WCMC) is the biodiversity assessment and policy implementation arm of the United Nations Environment Programme (UNEP), the world's foremost intergovernmental(More)
I n t r o d u c t i o n Omeprazole is a benzimidazole derivative used as an antisecretory agent for the treatment of peptic acid disorders. It is metabolized by the cytochrome P-450 system in the liver. Like other imidazoles, omeprazole has the potential to inhibit the metabolism of some drugs by a competitive mechanism at the hepatic microsomal enzyme(More)
The aim of this study was to evaluate bone mass changes after 1 year of four different types of pharmacological intervention. Ninety-seven prostate cancer patients treated with androgen deprivation therapy, and severe osteopenia or osteoporosis were retrospectively studied. Patients were divided in four groups. Group 1: 28 patients treated with denosumab,(More)
  • 1